Mission Therapeutics’ Post

Acute diseases often present suddenly and escalate quickly, making the need for a timely diagnosis and treatment plan critical, yet difficult to navigate. QuantHealth plays a major role in identifying and characterizing at-risk populations in acute disease management. Through our partnership with 4P-Pharma, for example, we continue to optimize the use of Plerixafor, typically used in cancer treatment, for Acute Respiratory Distress Syndrome (ARDS). To learn more about QuantHealth’s focus on the unmet needs of the pharmaceutical industry and the patients we aim to treat, message us or visit https://quanthealth.ai/

We have a new blog post! 🎉 Want to learn about Colony-Stimulating Factor Receptors and their uses in drug discovery? Click the link below! https://lnkd.in/du6uQfKZ

🚀 Exciting News! CytoImmune Partners with Hemostemix 🚀 We're thrilled to announce our partnership with Hemostemix Inc. to re-establish production of ACP-01 in our cutting-edge clinical cell manufacturing facility. Patients can expect access to this groundbreaking therapy by 2025. Globally, 236 million suffer from Peripheral Arterial Disease. Approximately 10% of these patients degenerate into CLTI. The incidence of CLTI in the U.S.A. is 1.33%, with an annual 10-40% amputation rate, and an annual 15-20% mortality rate. Globally, CLTI has a 60% mortality rate in 5 years. Therefore, saving a limb is saving a life. In Hemostemix's phase II clinical trial of ACP-01, 83% of patients followed for up to 4.5 years by the University of Toronto and University of British Columbia experienced healing of ulcers, cessation of pain, no major amputation, and improved. #HealthcareInnovation #Partnership #RegenerativeMedicine

Very pleased to be part of this effort with EBF. As a longtime advocate for rethinking the immunogenicity paradigm, it's great to see this level of traction in reframing immunogenicity as a biomarker with a view to ensuring everything we do is focused on value-added efforts for patients. https://lnkd.in/eiC9BfRD #BeAScientist #Immunogenicity #Biomarkers #RethinkingBioanalysis

#NRSN - NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS The Promising Results from the 12Month PARADIGM Study Highlight PrimeCs Potential as a Disease Modifying Drug https://buff.ly/3VLYh39 NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug PR Newswire Disease progression was slowed by 36% (p=...

Most highly effective therapies for multiple sclerosis successfully reduce relapse rates, but this does not always prevent disease progression. This is often due to PIRA or "progression independent of relapse activity". The findings of a small study of a novel antibody, frexalimab, show it may have the potential to achieve both outcomes. Phase III trials in relapsing MS and non-relapsing secondary progressive MS are ongoing, so we look forward to monitoring their progress and providing updates once results are published. #multiplesclerosis #ms #antibody #frexalimab #medicalresearch #scientificresearch #treatments

Gene&Cell Therapy >> Meet this year’s Endpoints 11; J&J winds down cardiovascular and metabolic unit; BMS wins schizophrenia approval; and more : Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here. We’re back with our take on this year’s up-and-coming biotechs. Our reporters spent months reviewing hundreds of nominations and talking to investors and biotech veterans about what makes a great biotech startup. Meet the 2024 Endpoints 11  This year’s Endpoints 11 class is making big bets and pursuing interesting new science. Want to learn more about three young AI companies flush with cash, a big neuroscience bet, or an intriguing approach to in vivo CAR-T? Check out our full list here. BMS wins approval for schizophrenia drug Some of our Endpoints 11 winners celebrated as their old company, Karuna Therapeutics, scored a win on Thursday for its schizophrenia drug. The FDA approved the first new schizophrenia drug in decades, Bristol Myers Squibb and Karuna’s Cobenfy. The pharma giant acquired the drug in its $14 billion takeover of Karuna last year. Cobenfy works differently than other schizophrenia drugs on the market and has a price tag of $1,850 for a 30-day supply, or $22,500 annually. BMS is projecting “multibillion-dollar” peak sales. J&J winds down cardiovascular and metabolic unit Johnson & Johnson is shutting down its pharma division’s cardiovascular and metabolic unit, marking at least the second large restructuring for the pharma group following the closure of its infectious disease and vaccine unit last year. The change primarily impacts the sales, marketing and medical affairs teams, who have been notified, a person familiar with the matter told Endpoints News’ Max Bayer. Pfizer pulls sickle cell treatment from the market  Pfizer decided on Wednesday to pull its sickle cell drug Oxbryta from all markets worldwide, after data showed an “imbalance” of fatalities and complications common to the disease. The decision is likely to diminish the value of Pfizer’s $5.4 billion purchase of Global Blood Therapeutics in 2022. Regulators followed up with their own alerts, including the FDA which advised health care professionals to stop prescribing the treatment. Bluebird bio cuts costs again Amid a broader downturn in cell and gene therapy companies, bluebird bio once again cut costs and laid off staff. The company said 25% of its workforce will not return and expenses — including R&D costs — will be trimmed by 20%. Once a $10 billion company, bluebird’s market cap fell below $100 million this week. SPOTLIGHT * Q&A: Bristol Myers’ tech chief on the promises and perils of AI bio * You bet your life: After I was diagnosed… #lucidquest #genetherapy #celltherapy

🌟 Advancing Drug Discovery in Liver Disease: The MASH CALL Initiative 🌟   🔍 Identifying the best candidates early on to minimize attrition rates is one of the biggest challenges in #drugdiscovery. To address this, there's an increasing need for advanced in vitro 3D models that can reliably predict clinical outcomes. These models need to be #scalable and #costeffective, compatible with #automation, and capable of delivering diverse readouts for complex phenotypic analysis. Our 3D InSight™ MASH model consists of primary human ✔️hepatocytes, ✔️Kupffer cells, ✔️endothelial cells, and ✔️stellate cells. These healthy liver spheroids are exposed to steatotic and pro-inflammatory media conditions, which over 🗓10 days result in the main hallmarks of human MASH (steatosis, inflammation, and fibrosis). At InSphero we take the next step in drug discovery for MASH by launching the MASH CALL Initiative – an exciting opportunity to push the boundaries of what's possible in drug discovery and bring new, effective treatments to the market faster 🚀   Join the MASH CALL by 🗓 September 6 and let's work together to revolutionize the future of MASH therapeutics! 💊 Learn more via the link in comments 👇 Francisco Verdeguer Radina Kostadinova, PhD Jesus Francisco Glaus Garzon Angelina Freitag Joel Zvick Philip Vonschallen Paul Edgard Clémençon Arumugham (Ragoo) Raghunathan Bärbel Ulmer Christine Schwenk Sue Grepper, PhD Madhu Lal Nag, MBS PhD Jan Lichtenberg Rositsa Hadzhipetrova Tina Žel #DrugDiscovery #Innovation #Healthcare #MASHCALL #Pharma #3DModels #PhenotypicAnalysis

Can Ivermectin help treat Parkinson’s Disease patients? The preclinical research certainly seems to suggest it can. Given that Ivermectin is safe even at high doses, there is very little downside for a Parkinson’s Disease patient to trying an escalating dose regimen, starting at 0.5mg/kg/day and then gradually scaling upwards. https://lnkd.in/ef2YYpBE

AbbVie announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ®; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remission from week 12 through week 52 in adults with giant cell arteritis (GCA). Upadacitinib is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Chemenu team is always committed to developing more compounds for drug discovery. Here come the related building blocks we can provide: https://lnkd.in/dnMW2aEi 👇 #Chemenu #AbbVie #positivetop-lineresults #SELECT-GCA #upadacitinib #RINVOQ #steroidtaperregimen #primaryendpoint #giantcellarteritis #JAKinhibitor #immunemediatedinflammatorydiseases #drugdiscovery #buildingblocks